NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY

Livia Lontai  1     Lorant Gonczi  1     Fruzsina Balogh  1     Nora Komlodi  1     Tamás Resál  2     Klaudia Farkas  2     Tamás Molnár  2     Pal Miheller  1     Petra Anna Golovics  3     Eszter Schäfer  3     Tamás Szamosi  3     Ákos Iliás  1     Peter L Lakatos  4    
1 Semmelweis University, Budapest, Hungary
2 University of Szeged, Szeged, Hungary
3 Hungarian Defence Forces Medical Centre, Budapest, Hungary
4 McGill University Health Center, Montreal, Canada

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing